Dionex is pleased to announce the
release of Application Update 178:
Faster Solution with Increased Resolution for
Determining Chromatographic Identity and Absence of OSCS in Heparin Sodium. The
U.S. Pharmacopeia Monograph for Heparin Sodium was revised after oversulfated chondroitin
sulfate (OSCS)-contaminated heparin led to the deaths of over 100 patients.
The method demonstrated in AU 178 achieves better resolution of
heparin, dermatan sulfate, and OSCS using the higher-capacity
Dionex IonPac® AS11-HC column, instead of the L61 column (e.g., IonPac
AS11 column) specified in the monograph. In addition to improved resolution,
the method is significantly faster, and it replaces the sodium perchlorate
eluent with a more environmentallyfriendly sodium chloride eluent.
For more information, visit
www.dionex.com or
contact your local Dionex representative.
Dionex (NASDAQ:DNEX) is a global leader in the manufacturing and
marketing of liquid chromatography and sample preparation systems, consumables,
and software for chemical analysis. The company's systems are used worldwide in
environmental analysis and by the life sciences, chemical, petrochemical, food
and beverage, power generation, and electronics industries. Our expertise in applications
and instrumentation helps analytical scientists to evaluate and develop
pharmaceuticals, establish environmental regulations, and produce better
industrial products.
IonPac
is a registered trademark of Dionex Corporation.
